EU initiates lawsuit against Astrazeneca for breach of contract

On Monday, the EU Commission announced that it has initiated a lawsuit against Swedish-British pharmaceutical company Astrazeneca.


In the lawsuit, the EU accuses Astrazeneca of failing to live up to their agreements concerning the supply of Covid-19 vaccine doses. The firm also stands accused of having no credible plan for delivering the doses within an acceptable time frame.

The contract stated that the pharmaceutical company was obligated to provide 180 million vaccine doses to the EU in the second quarter this year for EUR 300m (USD 362.4m).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs